ClinicalTrials.gg
RecruitingNCT07208773Updated Jun 18, 2026

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

A Phase 1/2 interventional study of YL201 and Ivonescimab in Advanced Solid Tumors, Non Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
435th of 1,593
260 · median 100
Started
2025
with 207 others
Phase 1/2
160 of 1,880
83 open now
Primary completion
2027-01
later than 493 of 986 live
Registered
1,642nd of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 435th largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 208 that started in 2025, is one of 160 in phase 1/2, reaches primary completion later than 493 of the 986 other live ones, and was the 1,642nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

03

Conditions studied

  • Advanced Solid Tumors
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer

Keywords

  • Advanced solid tumors
  • PD1/VEGF Bispecific
  • Antibody drug conjugate
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Inclusion criteria for the study population: Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.
  3. PS score is 0 or 1.
  4. Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.

Exclusion criteria

Exclusion Criteria:

  1. Suitable for local curative treatment.
  2. Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).
  3. Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.
  4. Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) [anti-PD-(L)1] or other .
  5. History of bleeding tendency or coagulation disorders and/or bleeding symptoms or risks within 4 weeks before randomization.
  6. Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels.
  7. Active disease requiring systemic treatment.
  8. or spinal cord compression.
  9. Patients with uncontrolled or clinically significant cardiovascular diseases.
  10. Clinically significant concurrent pulmonary diseases.
  11. Known to have active pulmonary tuberculosis. Other protocol-defined inclusion/ exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Phase 1: Safety run-in

    Multiple dose levels of YL201 will be explored in combination with Ivonescimab administered intravenously (IV) at a fixed dose.Participants receive YL201 and Ivonescimab (AK112) on Day 1 of each 3-week cycle, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent as specified in the protocol.

    Drug: YL201 · Drug: Ivonescimab

  • Experimental
    Phase 2: Dose expansion

    YL201 will be administered at the selected RDE in combination with Ivonescimab administered IV at a fixed dose. Participants receive YL201+ Ivonescimab (AK112) on Day 1 of each 3-week cycle, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent as specified in the protocol.

    Drug: YL201 · Drug: Ivonescimab

Interventions

  • DrugYL201

    YL201 will be administered as IV infusion

  • Ivonescimab will be administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    AEs are assessed based on NCI CTCAE v5.0.

    Time frame: Approximately within 36 months

  2. Maximum tolerate dose(MTD)

    Time frame: Approximately within 36 months

  3. Recommended Dose for Expansion

    Time frame: Approximately within 36 months

  4. Objective Response Rate (ORR)

    ORR defined as the proportion of subjects who achieve a best overall response (BOR) of complete response (CR) or partial response (PR).

    Time frame: Approximately within 36 months

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUC)

    Time frame: Approximately within 36 months

  2. maximum concentration (Cmax)

    Time frame: Approximately within 36 months

  3. minimum concentration at trough (Ctrough)

    Time frame: Approximately within 36 months

  4. Volume of distribution (Vd)

    Time frame: Approximately within 36 months

  5. plasma clearance (CL)

    Time frame: Approximately within 36 months

  6. half-life (t1/2)

    Time frame: Approximately within 36 months

  7. Time to peak drug concentration (Tmax)

    Time frame: Approximately within 36 months

  8. Investigator-assessed progression-free survival (PFS)

    PFS defined as the time interval from the first study drug administration to the first documented PD or death due to any cause, whichever occurs first

    Time frame: Approximately within 36 months

  9. Investigator-assessed overall survival (OS)

    OS defined as the time interval from the first study drug administration to death due to any cause.

    Time frame: Approximately within 36 months

  10. Investigator-assessed disease control rate (DCR)

    DCR defined as the proportion of subjects with a BOR of CR, PR, or stable disease (SD).

    Time frame: Approximately within 36 months

  11. Investigator-assessed time to response (TTR)

    TTR defined as the time interval from the first study drug administration to the first documentation of response (CR or PR).

    Time frame: Approximately within 36 months

  12. Investigator-assessed the depth of response (DpR) per RECIST v1.1

    The percentage change in target lesion size

    Time frame: Approximately within 36 months

  13. number of subjects who are Anti-Drug Antibody (ADA)-positive at any time

    Time frame: Approximately within 36 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 15 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Oct 29, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07208773
Collaborators
Akesobio
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Oct 29, 2025
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

MediLink Threrapeutics
Contact
clinicaltrials@medilinkthera.com
+86 512 62858368

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion